{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:35:20Z","timestamp":1774262120597,"version":"3.50.1"},"reference-count":157,"publisher":"Baishideng Publishing Group Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJV"],"published-print":{"date-parts":[[2021,1,25]]},"DOI":"10.5501\/wjv.v10.i1.1","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T09:39:07Z","timestamp":1611221947000},"page":"1-29","source":"Crossref","is-referenced-by-count":7,"title":["Emerging therapeutics in the management of COVID-19"],"prefix":"10.5501","volume":"10","author":[{"given":"Asim","family":"Kichloo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Albosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Aljadah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zain","family":"El-Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Wani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakeel","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagmeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akif","family":"Kichloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004500"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"B4","unstructured":"U.S. Food and Drug Administration.   Emergency Use Authorization. [cited 2020 July 16]. Available from: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization#coviddrugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204405"},{"key":"B6","unstructured":"Sanofi-Aventis Canada Inc.   KEVZARATM. [cited 2020 July 16]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00037766.PDF"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0929-z"},{"key":"B10","unstructured":"Shares Magazine.   Sanofi and Regeneron provide update on U.S. Phase 2\/3 adaptive-designed trial in hospitalized COVID-19 patients. [cited 2020 July 15]. Available from: https:\/\/www.sharesmagazine.co.uk\/news\/market\/6894211\/Sanofi-and-Regeneron-provide-update-on-US-Phase-2-3-adaptive-designed-trial-in-hospitalized-COVID-19-patients"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26062"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S86438"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716653745"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.01.20048561"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2020.1711884"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.2.579-588.2001"},{"key":"B17","unstructured":"CytoDyn.   Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients. [cited 2020 July 16]. Available from: https:\/\/www.cytodyn.com\/newsroom\/press-releases\/detail\/405\/treatment-with-cytodyns-leronlimab-indicates-significant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1086\/652190"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00748-2"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2165\/11531280-000000000-00000"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez418"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.038"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443"},{"key":"B25","unstructured":"Southeast University, China.   Immunoregulatory Therapy for 2019-nCoV. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2020 July 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04268537 NLM Identifier: NCT04268537"},{"key":"B26","unstructured":"Kinevant Sciences GmbH.   Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2020 July 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04205851 NLM Identifier: NCT04205851"},{"key":"B27","unstructured":"Kinevant Sciences GmbH.   A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2020 July 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04351243 NLM Identifier: NCT04351243"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.12.945576"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.10.009"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015874"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02282-12"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.002"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.17.20037432"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2020.01012"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.060"},{"key":"B36","unstructured":"Guangzhou 8th People's Hospital.   The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection (ELACOI). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000  [cited 2020 March 31]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04252885 NLM Identifier: NCT04252885"},{"key":"B37","unstructured":"Jieming QU.   Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2020 April 1]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04260594 NLM Identifier: NCT04260594"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-020-2203-3"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.12250199.v1"},{"key":"B40","unstructured":"National Institutes of Health.   TMC-310911. [cited 2020 July 15]. Available from: https:\/\/aidsinfo.nih.gov\/drugs\/549\/tmc-310911\/0\/professional"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/d41587-020-00003-1"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000011"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000003"},{"key":"B44","unstructured":"First Affiliated Hospital of Zhejiang University.   Evaluating and Comparing the Safety and Efficiency of ASC09\/Ritonavir and Lopinavir\/Ritonavir for Novel Coronavirus Infection. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2020 July 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04261907 NLM Identifier: NCT04261907"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105617"},{"key":"B46","unstructured":"HeNan Sincere Biotech Co, Ltd.   A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2020 July 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04425772 NLM Identifier: NCT04425772"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.93.027"},{"key":"B48","unstructured":"Japanese Pharmaceuticals and Medical Devices Agency (PMDA).   Report on the Deliberation Results. [cited 2020 July 26]. Available from: https:\/\/www.pmda.go.jp\/files\/000210319.pdf"},{"key":"B49","unstructured":"National Center for Biotechnology Information.   PubChem Database. Favipiravir. [cited 2020 July 10]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Favipiravir"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0364-1"},{"key":"B51","unstructured":"American Society of Health-System Pharmacists.   Assessment of Evidence for COVID-19-Related Treatments. [cited 2020 July 26]. Available from: https:\/\/www.ashp.org\/-\/media\/assets\/pharmacy-practice\/resource-centers\/Coronavirus\/docs\/ASHP-COVID-19-Evidence-Table.ashx?la=en&hash=B414CC64FD64E1AE8CA47AD753BA744EDF4FFB8C"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007"},{"key":"B53","unstructured":"Ministry of Health, Turkey.   Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2020 July 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04411433 NLM Identifier: NCT04411433"},{"key":"B54","unstructured":"Stanford University.   Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2020 July 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04346628 NLM Identifier: NCT04346628"},{"key":"B55","unstructured":"King Abdullah International Medical Research Center.   FAvipiravir and HydroxyChloroquine Combination Therapy (FACCT). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2020 July 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04392973 NLM Identifier: NCT04392973"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1177\/0018578719841044"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104545"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716197"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.29.20085761"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01594"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1922083117"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13940-6"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.013679"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nature17180"},{"key":"B66","unstructured":"U.S. Food and Drug Administration.   Fact Sheet for Health Care Providers Emergency use Authorization (EUA) of Remdesivir. [cited 2020 July 27]. Available from: https:\/\/www.fda.gov\/media\/137566\/download"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"B69","unstructured":"National Institutes of Health.   NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19. [cited 2020 July 27]. Available from: https:\/\/www.nih.gov\/news-events\/news-releases\/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19"},{"key":"B70","unstructured":"Gilead Sciences.   Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734\u2122) in Participants With Severe Coronavirus Disease (COVID-19). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited July 15, 2020]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04292899 NLM Identifier: NCT04292899"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2022236"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-020-09973-w"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2174\/1574888X13666180913123424"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2020.0228"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01091"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/ijs.12065"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00345"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2012.64"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3727\/096368912X657369"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.025"},{"key":"B82","unstructured":"Athersys Inc.   MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) (MACoVIA). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2020 July 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04367077 NLM Identifier: NCT04367077"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c00272"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/35078107"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2008-3"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.17179\/excli2020-1328"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.2174\/138920011794520017"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/nbt831"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1021\/mp4006358"},{"key":"B90","unstructured":"National Cancer Institute.   Recombinant human angiotensin converting enzyme 2 APN01. [cited 2020 July 29]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/recombinant-human-angiotensin-converting-enzyme-2-apn01"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.04.004"},{"key":"B92","unstructured":"Apeiron Biologics.   Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (APN01-COVID-19). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2020 July 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04335136 NLM Identifier: NCT04335136"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.245639"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105945"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202004_21038"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(03)00806-5"},{"key":"B98","unstructured":"van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 1997; 24: 55-60"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/s0950-3579(05)80004-4"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-015-0239-y"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161063"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101766"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0111-8"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1080\/15563650500514558"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa478"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1849"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.8857"},{"key":"B109","unstructured":"Horby P, Landray M.   No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. [cited 2020 July 28]. Available from: https:\/\/www.recoverytrial.net\/news\/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016638"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800173-8.00001-5"},{"key":"B112","unstructured":"Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11: 137-152"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(96)80179-2"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.29.008631"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1857"},{"key":"B116","unstructured":"Singlas E. [Clinical pharmacokinetics of azithromycin]. Pathol Biol (Paris) 1995; 43: 505-511"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-7125(16)30040-2"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-98605-0_40"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2010.09.010"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2020.03.002"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.03.006"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/BF03190118"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102566"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1957.72980300006009b"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1456-4"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30317-2"},{"key":"B127","unstructured":"Yasir M, Goyal A, Bansal P, Sonthalia S.   Corticosteroid Adverse Effects 2020"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1979262232"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/BF00541537"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1210\/endo-76-5-852"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2004.062299"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.03.001"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.06.20032342"},{"key":"B134","unstructured":"Peking Union Medical College Hospital.   Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2020 April 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04244591"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-007-9000-9"},{"key":"B138","unstructured":"U S. Food and Drug Administration.   Stromectol (Ivermectin). [cited 2020 August 3]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/Label\/2008\/050742s022Lbl.pdf"},{"key":"B139","unstructured":"Drugbank.   ca. Ivermectin. [cited 2020 August 3]. Available from: https:\/\/www.drugbank.ca\/drugs\/DB00602"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006934"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks147"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20120150"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104787"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1271-9"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1490-9"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511812"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq106"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10044"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004168117"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-017-0350-x"},{"key":"B152","doi-asserted-by":"crossref","unstructured":"Napp LC, Bauersachs J.   Triple cannulation ECMO. In: Firstenberg M, editor. ECMO, InTech Open. 2016","DOI":"10.5772\/63392"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800385"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2020.04.003"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02925-3"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05979-7"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.03.011"}],"container-title":["World Journal of Virology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2220-3249\/full\/v10\/i1\/1.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T09:40:58Z","timestamp":1611222058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2220-3249\/full\/v10\/i1\/1.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":157,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5501\/wjv.v10.i1.1","relation":{},"ISSN":["2220-3249"],"issn-type":[{"value":"2220-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,25]]}}}